State Of The Union: Ovarian Cancer Patients Living Longer President Obama

Barron’s Medical Journal Reporting From Rice University Houston, Texas USA

---

State Of The Union: Ovarian Cancer Patients Living Longer President Obama:

Houston ( AP ) Jan. 21, 2014 /#PRNewswire/ (#GLOBE #NEWSWIRE) –---- ,Today Sam Houston Biotech A Houston based biotech company announced today they are now adding ovarian cancer to their genomic product line. There are many reasons for this additional product line says Rose Conrad CEO one in particular is that we feel The Afforable Care Act and Genomics can have Women back on their after Ovarian Cancer treatment. Sam Houston has developed a catalog of the genetic aberrations responsible for an aggressive type of ovarian cancer that accounts for 70 percent of all ovarian cancer.

Women with breast cancer diagnosed at age 50 or younger or ovarian cancer at any age meet expert guidelines for genetic counseling but this service is not specifically covered under the Affordable Care Act

Genomics and Aberrant Genes are the key. Aberrant Genes are genes expressed at the wrong time or inappropriately. By detecting the aberrant genes in a patient, and targeting these genes with therapies that are most effective against the specific mutations.

Sex can feel different after ovarian cancer surgery. Your vagina will be a bit shorter. But it is naturally very stretchy so this shouldn't make too much difference to you and your partner. But remember that having your womb removed means that you will have stitches at the top of your vagina where your cervix was taken out. So you shouldn't have full sex until these have healed. This takes about 3 or 4 weeks. Is what most doctors tell their patient.

Ovarian cancer is the fifth leading cause of cancer death among women in the U.S., with almost 22,000 new cases and 14,000 deaths estimated for 2010 according to the National Cancer Institute. High-grade serous ovarian cancer, which begins in the cells on the surface of the ovary, accounts for 90 percent of all ovarian cancers and often remains undetected until it’s quite advanced.

Condrad suggest here we can win, 62% of Ovarian Cancer Patients Under 30 are choosing to freeze entire ovaries or strips of ovarian tissue. A woman diagnosed with early-stage ovarian cancer removal of one ovary has become a real option. This conservative surgery greatly increases the chances of preserving fertility.

There is a 12 percent Chance that the patient will have a recurrence in their remaining ovary and subsequently may die. Most women resumed normal menstruation or had a successful pregnancy.

A network of genes that repairs damaged DNA is defective in about half the tumors. Patients with this defect may benefit from therapies that inhibit this errant function. And they found that the spectrum of mutations in high-grade serous ovarian cancer is distinct from three other ovarian cancer subtypes, which are themselves distinct from each other.

But you may find that you don't feel ready to start being sexually active again that soon. It takes many women much longer than that. You may still have a bit of discomfort, so prefer to wait a bit longer. And you will need to recover emotionally as well as physically. SuperBowl Weekend Kristen Mills In NYC You may feel that your womb was an important part of your body and having had it taken away can affect how you feel about yourself sexually. You will no longer be able to become pregnant. And you won't have any more periods. Even if you were past your menopause before the surgery, losing your womb can be a very emotional experience. Many women find this more of a shock than they expected

The molecular aberrations that cause ovarian cancer is critical for developing and deploying therapies that will improve patients’ lives. The Cancer Genome Atlas project has analyzed messenger RNA expression, microRNA expression, promoter methylation and DNA copy number in 489 high-grade serous ovarian adenocarcinomas and the DNA sequences of exons from coding genes in 316 of these tumors. Here we report that high-grade serous ovarian cancer is characterized by TP53 mutations in almost all tumors (96%); low prevalence but statistically recurrent somatic mutations in nine further genes including NF1, BRCA1, BRCA2, RB1 and CDK12; 113 significant focal DNA copy number aberrations; and promoter methylation events involving 168 genes. Analyses delineated four ovarian cancer transcriptional subtypes, three microRNA subtypes, four promoter methylation subtypes and a transcriptional signature associated with survival duration, and shed new light on the impact that tumors with BRCA1/2 (BRCA1 or BRCA2) andCCNE1 aberrations have on survival.

Chemotherapy (chemo) is the use of drugs to treat cancer. Most often, chemo is a systemic treatment − the drugs are given in a way that allows them to enter the bloodstream and reach all areas of the body. Systemic chemo can be useful for cancers that have metastasized (spread). Most of the time, systemic chemo uses drugs that are injected into a vein (IV) or given by mouth. For some cases of ovarian cancer, chemotherapy may also be injected through a catheter directly into the abdominal cavity. This is called intraperitoneal (IP) chemotherapy. Drugs given this way are also absorbed into the bloodstream, so IP chemotherapy is also a type of systemic chemo.

Among the services included in these regulations are genetic counseling and testing for inherited breast and ovarian cancer risk in women with a family history of cancer. Breast and ovarian cancers have been linked to mutations in the BRCA1 and BRCA2 genes.

The Ovarian Cancer National Alliance, FORCE, Bright Pink and CCARE Lynch Syndrome applaud the government’s attention to women’s health services in general and preventive services in particular. We are happy that genetic counseling and genetic testing will be covered without cost-sharing, as these are important services for women who may have an increased risk of ovarian and breast cancers. The new regulations are a step in the right direction, but they have only taken us halfway there. We are concerned that the current regulations do not include the following:

• genetic counseling or testing in people with a family history indicative of Lynch Syndrome (which is associated with colon, uterine, and ovarian cancer) or other hereditary cancer syndromes;

• genetic counseling and testing for women who have already been diagnosed with cancer;

• risk-management services such as increased surveillance and prophylactic surgery which has been proven to reduce the risk for developing cancer and the risk of dying in high-risk women; and

• genetic counseling and testing in men. As organizations representing thousands of women and families who have or are at risk of developing hereditary cancer, we will continue to work with appropriate government agencies to ensure coverage of evidence-based services that reduce people’s risk for cancer.

The preventive services covered under the Affordable Care Act are based on recommendations from the United States Preventive Services Task Force and include women with the following risk factors:

• Ashkenazi Jewish women with one first degree relative or two second degree relatives on the same side of the family with breast or ovarian cancer • Non-Ashkenazi Jewish women who have:

• two first-degree relatives who had breast cancer; at least one of these two were diagnosed before age 50;

• three or more first- or second-degree relatives with breast cancer regardless of age at diagnosis;

• a combination of both breast and ovarian cancer among first- and second-degree relatives;

• a first-degree relative with bilateral breast cancer;

• a combination of two or more first- or second- degree relatives with ovarian cancer, regardless of age at diagnosis;

• a first- or second- degree relative with both breast and ovarian cancer at any age; or

• a history of breast cancer in a male relative

These guidelines are based on USPSTF’s Genetic Risk Assessment and BRCA Mutation Testing for Breast and Ovarian Cancer Susceptibility recommendations released in 2005. The USPSTF is currently reviewing these guidelines. Revisions in the guidelines could impact preventive services covered by the Affordable Care Act and services available to Medicare beneficiaries. .

People who are concerned that the cancer in their family could be hereditary should consult with a qualified genetics professional prior to proceeding with genetic testing for cancer risk.

Where Did That Lump Come From On Your Breast

Barron’s Medical Journal Reporting From Duke University Durham, NC USA

---

Where Did That Lump Come From On Your Breast

---

Durham NC ( AP) Ninety Seven Percent of people asked by Barron’s Medical Journal, said they would like to know where dose that Lump come from on A Breast Cancer patient breast? BMJ asked The CEO Of Sam Houston Biotech Inc A Houston Texas Base Biotech Company Located in The Houston Medical Center. The Question Where dose that lump come from on your Breast ? How does that lump get on to your breast ?

Conrad responded with a smile on her face and said let's open up the breast cancer playbook.

Oncogene are genes that take your genes and DNA then convert your genes to breast cancer genes. The most known genes associated with breast cancer is the KCNK9 Gene. KCNK9 encodes a potassium channel that allows the breast cancer tumor to grow on your breast. This process is aided by Hypoxia. Hypoxia refers to an inadequate oxygen supply to the cells and tissues of the Breast.

The Main Gene that stops the growth of KCNK9 Genes is gene is p53. p53 is a fundamental determinant of cancer susceptibility, p53 integrates stress signals and elicits apoplectic responses that maintain genomic stability. When cells sense a decrease in oxygen availability (hypoxia), they develop adaptive responses in order to sustain this condition and survive. If hypoxia

lasts too long or is too severe, the cells eventually die. Hypoxia is also known to modulate the p53 pathway, in a manner dependent or not of HIF-1 (hypoxia-inducible factor-1), the main transcription factor activated by hypoxia. The p53 protein is a transcription factor, which is rapidly stabilized by cellular stresses and which has a major role in the cell responses to these stresses. This process is why it is important Conrad says for people that are first degree relatives of breast cancer patients, must take a genomic test to see if they are the carrier of gene KCNK9. By identifying this gene we can direct patients with the correct advise as to deal with the fact that they have a lunp on the breast to they are going to get a lump on their breast. Often what happens is that a breast cancer patients dose not go to the doctor or take important test to see if there is a lump on the breast. what happens

is the spread of breast cancer is responsible for more than 90 percent of breast cancer deaths. The process by which breast cancer spreads -- or metastasizes is where Metastasis was long thought as a late event in breast cancer progression, With Genomics we now shown metastasis to be an early event that is dependent on Hypoxia HIF-1. HIF-1 protein controls genes that enable cells to survive in low oxygen, like cells in solid breast tumors. In order for breast cancer cells to spread to lungs, they must leave the breast,enter blood vessels that lead to the lungs, and exit those same vessels. "

What is A Gene ? A gene is the molecular unit of heredity of a living organism. It is widely accepted by the scientific community as a name given to some stretches of deoxyribonucleic acids (DNA) and ribonucleic acids (RNA) that code for a polypeptide or for an RNA chain that has a function in the organism, though there still are controversies about what plays the role of the genetic material.[1]Living beings depend on genes, as they specify all proteins and functional RNA chains

Gene encodes a protein that contains multiple transmembrane regions and two pore-forming P domains and functions as a pH-dependent potassium channel. Amplification and overexpression of this gene have been observed in several types of human carcinomas. This gene is imprinted in the brain, with preferential expression from the maternal allele. A mutation in this gene was associated with Birk-Barel mental retardation dysmorphism syndrome. Alternative splicing results in multiple transcript variants

What is A Protein? Proteins are a large biological molecules, or macromolecules, consisting of one or more chains of amino acidresidues. Proteins perform a vast array of functions within living organisms, including catalyzing metabolic reactions, replicating DNA,responding to stimuli, and transporting molecules from one location to another. Proteins differ from one another primarily in their sequence of amino acids, which is dictated by the nucleotide sequence of their genes, and which usually results in folding of the protein into a specific three-dimensional structure that determines its activity.

Blood vessels are pretty tight; a cell has to work pretty hard to get through the vessel wall. How this process works is breast cancer cells turn on genes called ANGPTL4, ANGPTL4, helps breast cancer to travel through blood vessel walls. Research is now being performed with Genomics. The Sam Houston Biotech Team found by injecting these cells either with normal or "knocked-down" levels of ANGPTL4 into mice and examining their lungs. Cells lacking HIF-1 and containing extra ANGPTL4 were better able to invade the lungs than cells without extra ANGPTL4. There are other genes that are involved in the creation of a breast cancer tumor on the breast. Her-2, p63, 73. Conrad goes on to say that in their genomic test uses 21 different genes to project ,stop the growth and the spread of a patients breast cancer Lump. HIF-1 as a therapeutic target can extend the life of many stage four breast Cancer patients.
Sam Houston discovered The tumor suppressors VHL (von Hippel-Lindau protein) and p53 target HIF-1α for ubiquitination to inactivation breast cancer tumors cells increases the of HIF-1. This process Increased phosphatidylinositol 3-kinase (PI3K) and AKT. In breast cancer, increased activity of the HER2 (also known as neu) receptor tyrosine kinase is associated with increased tumor grade, chemotherapy resistance, and decreased patient survival. HER2 has also been implicated as an inducer of VEGF expression. Sam Houston demonstrate that HER2 signaling induced by over expression in mouse 3T3 cells or human MCF-7 breast cancer cells results in increased HIF-1α protein and VEGF mRNA expression that is dependent upon activity of PI3K, AKT (also known as protein kinase B), and the downstream kinase FRAP (KBPS-rapamycin-associated protein)
Sam Houston concern with patients with diabetes and breast cancer may not receive full Benefit of HIF-1. All women having access to a physician can have access to HIF-1 treatments


Proteomics is the large-scale study of proteins, particularly their structures and functions.[1][2] Proteins are vital parts of living organisms, as they are

the main components of the physiological metabolic pathways of cells. The term proteomicswas first coined in 1997[3] to make an analogy with genomics, the study of the genome. The word proteome is a blend ofprotein and genome